Effect of Angiotensin Receptor Inhibitors on Endothelial Dysfunction

Effect of Angiotensin Receptor Inhibitors on Endothelial Dysfunction

Background: Children and teenager with diabetes type I (IDDM or Insulin dependent diabetes mellitus) are strongly at risk for diabetic nephropathy in adolescents and adulthood. Treatment of endothelial dysfunction can increase the longevity of these patients. The aim of this study was to evaluate th...

Full description

Bibliographic Details
Main Authors:	Alaleh Gheisari, Shaghayegh Haghjooy Javanmard, Rouhollah Shirzadi, Masoud Amini
Format:	Article
Language:	fas
Published:	Vesnu Publications 2011-10-01
Series:	مجله دانشکده پزشکی اصفهان
Subjects:	Valsartan Endothelial dysfunction Angiotensin receptor blockers
Online Access:	http://jims.mui.ac.ir/index.php/jims/article/view/1051

Similar Items

The effects of blocking angiotensin receptors on early stages of diabetic nephropathy
by: Alaleh Gheissari, et al.
Published: (2012-01-01)

Angiotensin receptor blockers & endothelial dysfunction: Possible correlation & therapeutic implications
by: Miroslav Radenkovic, et al.
Published: (2016-01-01)

EFFECT OF ANGIOTENSIN RECEPTOR BLOCKADE ON ENDOTHELIAL FUNCTION: FOCUS ON OLMESARTAN MEDOXOMIL
by: C. Ferrario
Published: (2010-12-01)

Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real‐world study in Taiwan
by: Po‐Cheng Chang, et al.
Published: (2020-10-01)

Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials
by: Rodolfo Pedro Rothlin, et al.
Published: (2021-03-01)

Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation
by: Isabella Viana Gomes Silva, et al.
Published: (2019-07-01)

Efficacy and safety of valsartan/amlodipine single-pill combination in patients with essential hypertension (PEAK LOW)
by: Pınar Kızılırmak, et al.
Published: (2014-06-01)

Valsartan: come versatilità e tollerabilità possono contribuireal contenimento della spesa sanitaria
by: Francesco Vittorio Costa
Published: (2011-03-01)

Well-Known and Novel Players in Endothelial Dysfunction: Updates on a Notch(ed) Landscape
by: Francesca Fortini, et al.
Published: (2021-08-01)

Treating Ebola patients: a ‘bottom up’ approach using generic statins and angiotensin receptor blockers
by: David S. Fedson, et al.
Published: (2015-07-01)

Angiotensin II Induces Oxidative Stress and Endothelial Dysfunction in Mouse Ophthalmic Arteries via Involvement of AT1 Receptors and NOX2
by: Michael Birk, et al.
Published: (2021-08-01)

Perspectives of using angiotensin receptor antagonists
by: V V Fomin
Published: (2009-06-01)

Sartans: differences, similitudes and costs
by: Orietta Zaniolo, et al.
Published: (2008-06-01)

CARDIOVASCULAR PATIENT WITH STAGE 1-3 CHRONIC KIDNEY DISEASE: CONTEMPORARY CARDIONEPHROPROTECTION IN REAL CLINICAL PRACTICE
by: E. I. Tarlovskaya
Published: (2016-09-01)

Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis
by: Wipharak Rattanavipanon, et al.
Published: (2021-07-01)

ARB Compared with non-ARB in Preventing Cardiac Events in High Risk Hypertensive Patients: An Evidence Based Case Report
by: Alvin Nursalim, et al.
Published: (2013-06-01)

Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study
by: S Bhuvaneshwari, et al.
Published: (2018-07-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
by: Martin C.S. Wong, et al.
Published: (2020-10-01)

ENDOTHELIAL DYSFUNCTION AND ROLE NITRATES AND BETA-BLOCKERS IN ITS CORRECTION IN ISCHEMIC HEART DISEASE
by: A. N. Britov
Published: (2016-05-01)

Protective Effects of Short-Chain Fatty Acids on Endothelial Dysfunction Induced by Angiotensin II
by: Iñaki Robles-Vera, et al.
Published: (2020-04-01)

The role of tissue renin angiotensin aldosterone system in the development of endothelial dysfunction and arterial stiffness
by: Annayya R Aroor, et al.
Published: (2013-10-01)

Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor
by: Jingchao Sun, et al.
Published: (2020-09-01)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021-09-01)

Comparative analysis of the efficiency of the selective b-blocker nebivolol and the angiotensin II receptor blocker valsartan in men with hypertension, metabolic syndrome, and erectile dysfunction
by: S. V Nedogoda, et al.
Published: (2013-06-01)

Activation of Yes-Associated Protein/PDZ-Binding Motif Pathway Contributes to Endothelial Dysfunction and Vascular Inflammation in AngiotensinII Hypertension
by: Qian Xu, et al.
Published: (2021-09-01)

Evaluation of Blood Pressure Changes Using Ambulatory Blood Pressure Monitoring (ABPM) in Children Undergoing Kidney Transplantation and its Relationship with Left Ventricular Mass Index, and Level of Serum Angiotensin and Atrial Natriuretic Peptide
by: Alaleh Gheisari, et al.
Published: (2012-03-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

SARTANS AND ANGIOTENSIN CONVERTING ENZYME INHIBITORS: A DUEL BETWEEN TWO LEADERS OF PHARMACOTHERAPY OF CARDIOVASCULAR DISEASES
by: K. A. Gyamdzhyan, et al.
Published: (2015-12-01)

A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors
by: Siragy H
Published: (2011-05-01)

Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients
by: Wenjun Wang, et al.
Published: (2021-01-01)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
by: Zhang C, et al.
Published: (2021-02-01)

Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer
by: Hiroji Uemura, et al.
Published: (2011-12-01)

Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer
by: Hiroji Uemura, et al.
Published: (2011-12-01)

Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease
by: Pei-Tzu Wang, et al.
Published: (2012-09-01)

Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions
by: Athanasios Feidakis, et al.
Published: (2021-01-01)

Management of hypertension: Insights into prescribing behavior with focus on angiotensin receptor blockers
by: S Ramakrishnan, et al.
Published: (2017-01-01)

Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program
by: Abraham I
Published: (2011-03-01)

Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Contrast-Induced Nephropathy
by: Letian Zhou, et al.
Published: (2014-03-01)

A1166C POLYMORPHISM OF THE GENE FOR ANGIOTENSIN II RECEPTOR 1ST TYPE AND ENDOTHELIAL DYSFUNCTION IN MEN WITH A HISTORY OF MYOCARDIAL INFARCTION IN YOUNG AGE
by: O. A. Berkovich, et al.
Published: (2000-12-01)